Glaxosmithkline Pharmaceuticals Ltd vs Zenotech Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 13, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2406 as of 13 May 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Zenotech Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Zenotech Laboratories Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of Zenotech Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of Zenotech Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of Zenotech Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Zenotech Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Zenotech Laboratories Ltd

Zenotech Laboratories Limited was initially established as Sunline Technologies Limited in June, 1989 and changed to the present name w.e.f.
August 9, 2004.
Company is a loan licensing company catering exclusively to Sun Pharmaceutical Industries Limited, Promoter & holding company and they are specialized contract manufacturing services /processing in parenteral depot formulations, ophthalmic, oncology oral & injectables and general injectables.
Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. During financial year 2004-05, the Hon'ble High Court of Andhra Pradesh sanctioned the Scheme of Amalgamation with M/s.
Zenotech Technologies Limited with effect from November 1st , 2003.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Zenotech Laboratories Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Zenotech Laboratories Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,472 Cr while Market cap of Zenotech Laboratories Ltd is 274 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Zenotech Laboratories Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Zenotech Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Zenotech Laboratories Ltd?

As of May 13, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2448.1. On the other hand, Zenotech Laboratories Ltd stock price is INR ₹45.05.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Zenotech Laboratories Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Zenotech Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.